Even short-term hormone replacement therapy use associated with increased ovarian cancer risk
the ONA take:
A meta-analysis of 52 epidemiological studies on hormone replacement therapy (HRT) and ovarian cancer indicate that HRT use, even for less than 5 years, increased women’s risks of developing ovarian cancer. The reviewed studies represent virtually all the epidemiological evidence ever collected on HRT use and ovarian cancer.
The international Collaborative Group on Epidemiological Studies of Ovarian Cancer, involving more than 100 researchers worldwide organized by the University of Oxford, in the United Kingdom, analyzed individual participant data from 21,488 women with ovarian cancer, almost all from North America, Europe, and Australia.
Their findings indicate that women who use HRT for just a few years have an approximately 40% higher risk of developing ovarian cancer than women who have never taken HRT.
This increase in risk was seen in only the two most common types (serious and endometrioid ovarian cancers), and not in mucinous and clear cell ovarian cancers, which are less common types. Study co-author Professor Dame Valerie Beral, from the University of Oxford, suggests that the definite increase in risk of ovarian cancer has implications for the current efforts to revise guidelines for HRT use.
Women who use hormone replacement therapy for just a few years have an approximately 40% higher risk of developing ovarian cancer.
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|